Biographical Information Regarding Directors and Executive Officers
DR. ELAZAR RABBANI, Ph.D. is an Enzo Biochem founder and has served as the Company's Chairman of the Board and Chief Executive Officer since its inception in 1976 and Secretary since November 25, 2009. Dr. Rabbani has authored numerous scientific publications in the field of molecular biology, in particular, nucleic acid labeling and detection. He is also the lead inventor of many of the Company's pioneering patents covering a wide range of technologies and products. Dr. Rabbani received his Bachelor of Arts degree from New York University in Chemistry and his Ph.D. in Biochemistry from Columbia University. He is a member of the American Society for Microbiology.
BARRY W. WEINER, President, Chief Financial Officer, Principal Accounting Officer and Director and a founder of Enzo Biochem. He has served as the Company's President since 1996, and previously held the position of Executive Vice President. Before his employment with Enzo Biochem, he worked in several managerial and marketing positions at the Colgate Palmolive Company. Mr. Weiner is a member of the New York Biotechnology Association. He received his Bachelor of Arts degree in Economics from New York University and a Master of Business Administration in Finance from Boston University.
JAMES M. O'BRIEN, Mr. James M. O'Brien is Enzo's Executive Vice President, Finance and is responsible for leading and managing all activities for our Corporate and Business Unit Financial functions. Mr. O'Brien joined Enzo in 2014 as Senior Vice President, Finance and has compiled an extremely impressive background and brings over fifteen years of direct experience leading and managing all Financial functions for a number of diverse global organizations. Specifically, Mr. O'Brien has held leadership positions for Corporate and Business Unit budgeting and forecasting, SEC Reporting, Internal Controls and Accounting Operations for large and small multi-national public companies in pharmaceutical, consumer products and manufacturing industries. Most recently Mr. O'Brien was Vice President and Corporate Controller for Allergan, plc. (Formally Actavis, plc) a global specialty pharmaceutical company with revenues in excess of $8 billion. Previous roles for Mr. O'Brien included senior level Finance leadership for Nycomed US, Aptuit, Inc., Purdue Pharma LLP and Bristol Myers Squibb Company. Mr. O'Brien began his career in public accounting with PricewaterhouseCoopers LLP. Mr. O'Brien holds a BA from George Washington University and an MBA from Fordham University. Mr. O'Brien achieved his CPA in 1992.
DIETER SCHAPFEL, MD, Chief Medical Director for Enzo Clinical Labs, has been employed with the Company since 2012, initially as a consulting pathologist. Dr. Schapfel served as Medical Director of Pathology at Southside Hospital – North Shore/Long Island Jewish Health System from 2006 to 2012. Dr. Schapfel served as a staff pathologist at Huntington Hospital from January 2004 to June 2006. Dr. Schapfel served as Director of Pathology and Medical Affairs and the College of American Pathologists Director of Pathology, Dublin, Ireland and Farmingdale, NY for Icon Laboratories from February 2002 to October 2003. Dr. Schapfel is a graduate of the State University of New York at Stony Brook, College of Medicine, where he also served his residency. He is a diplomat of the American Board of Pathology with certification in Anatomic and Clinical Pathology and is also a diplomat of The National Board of Medical Examiners.
PAUL C. O'BRIEN, Vice President of Global Human Resources for Enzo Biochem Inc., since November 2009. Before joining the Company, Mr. O'Brien was Vice President of Global Human Resources at Black & Decker for their Fastening and Assembly Systems Group from 2005 to 2009. From 2003 to 2004, Mr. O'Brien was Director of Global Human Resources for Stryker Spine and from 1991 to 2002, Mr. O'Brien held various roles in Human Resources with Tyco Healthcare, the latest of which was Senior Director, Divisional Human Resources. Mr. O'Brien received a Bachelor of Arts degree in General Studies from Providence College.
KARA CANNON, Global Head of Sales and Marketing, has been employed with the Company since 2011 and is responsible for strategic and tactical marketing, as well as, Sales and Business Development for the Life Sciences products. Ms. Cannon previously held executive positions at Pall Corporation, where she focused on commercial operations within the areas of diagnostics, biotechnology and biosciences. She has also held marketing and technical positions at Dynal Biotech (now ThermoFisher Scientific). She has had extensive experience in the marketing and selling of innovative platforms for the diagnostics markets, as well as, the development and execution of strategic plans for the growth and sustainability of diagnostic-related businesses. Ms. Cannon holds a BA from Franklin and Marshall College.
MARK WELCH, Senior Director of Finance, started with the Company in 2014. Mark is responsible for non-clinical operations within Enzo Clinical Labs, as well as, the development and execution of corporate business strategy. Mr. Welch has extensive experience in Health Care service operations and finance. He previously held the position of Senior Director of Finance for Merck-Medco (now Express Scripts) reporting to the CMO. His healthcare experience also includes tenure at Becton Dickinson and Visiting Nurse Services of NY. His Financial Operations experience is complemented with extensive process improvement implementation, project management and organizational leadership. Mr. Welch holds an M.B.A. in Finance from Long Island University and a B.S. in Commerce from Niagara University.
BRUCE A. HANNA, Ph.D., has been a director of the Company since January 2017 and serves on the Audit, Nominating and Corporate Governance, and the Compensation Committee. He is the Chairman of the Nominating and Corporate Governance Committee. He is a Clinical Professor of Pathology and Clinical Professor of Microbiology at the New York University School of Medicine, Adjunct Professor of Basic Science at New York University College of Dentistry, and Adjunct Professor of Biology, Long Island University. From 2006 to 2015, he served on the ASM International Committee and WHO Global Committee, from 2000-2012 he served as an Editor of Clinical Microbiology Reviews, and 1982-2008 was Director of Clinical Microbiology, Immunology, and 2008-2010 was Interim Director of Pathology, Bellevue Hospital Center. Dr. Hanna, Ph.D. earned a Bachelor of Science in Biology from Saint Bonaventure University, a Masters in Science in Microbiology from Northeastern University, and a Ph.D. in Microbiology from Saint John’s University. Dr. Hanna’s post-doctorate work in Clinical Microbiology was at Mt. Sinai Hospital.
GREGORY M. BORTZ, has been a Director of the Company since January 2010 and currently serves on the Audit, Compensation and Nominating/Governance Committees and since November 2, 2010 has served as the Chairman of the Audit Committee. Mr. Bortz is the founder of and has been the managing partner of Creo Capital Partners, LLC ("CREO"), a private equity firm that provides capital to middle-market companies, since February 2005. CREO holds investments in companies certain of which Mr. Bortz serves as a board member. In addition, Mr. Bortz serves as the Chief Investment Officer of the CREO Select Opportunities Fund, a hedge fund that invests in public fixed income and equity securities. From October 2000 to February 2005, Mr. Bortz was Senior Vice President, Investment Banking Division of the international investment bank Lehman Brothers, Inc. Prior to such position he was a Vice President of Investment Banking at Credit Suisse First Boston, an international investment bank, from January 1998 to October 2000. Mr. Bortz held the position of Manager at the accounting firm of Ernst and Young (1994-1997) and Senior at the public accounting firm of Arthur Andersen (1993-1994), both in their respective audit groups. Mr. Bortz was qualified as a chartered accountant in England and Wales, and South Africa, and graduated from the University of Cape Town with a Bachelors of Business Science with Honors in Finance and Postgraduate Diploma in Accounting.
DOV PERLYSKY, has been a Director of the Company since September 2012 and since January 17, 2013 has served on the Audit, Nominating/Governance and Audit Committees and chairs the Nominating/Governance committee. Mr. Perlysky has served as a member of the board of directors of Pharma-Bio Serv, Inc. since 2004 and as a member of the board of directors of Highlands State Bank since 2010. Mr. Perlysky has also been the managing member of Nesher, LLC, a private investment firm, since 2000 and a director of Engex, Inc., a closed-end mutual fund, since 1999. From 1998 until 2002, Mr. Perlysky was a vice president in the private client group of Laidlaw Global Securities, a registered broker-dealer. Mr. Perlysky received his B.S. in Mathematics and Computer Science from the University of Illinois in 1985 and a Masters in Management from the J.L. Kellogg School of Management of Northwestern University in 1991. Mr. Perlysky is the son-in-law of Rosalind Davidowitz, see "Security Ownership of Certain Beneficial Owners and Management" on page 7 and footnotes 8 and 10 thereof. The Company believes that Mr. Perlysky is independent under the rules of the NYSE.